drugset / Trial / NCT07156539
A Phase 3 Study of HS-20094 in Patients With T2DM
RandomizedParallel-groupOpen-labelTreatment
Summary
The study is being conducted to evaluate the efficacy and safety of HS-20094 once weekly (QW) in subjects with type 2 diabetes mellitus not adequately controlled with metformin monotherapy or in combination with SGLT2 inhibitors compared to Dulaglutide QW for 44 weeks and 52 weeks.
Timeline
- Start
- 2025-09-30
- Primary completion
- 2027-03-30
- Completion
- 2027-05-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Dulaglutide | Peptide | — | Subcutaneous |
| Subject | Olatorepatide | Protein / enzyme biologic | — | Subcutaneous |